Novel Human Parechovirus 3 Diversity, Recombination, and Clinical Impact Across 7 Years: An Australian Story
File version
Version of Record (VoR)
Author(s)
May, Meryta
Tozer, Sarah
Day, Rebecca
Bernard, Anne
Zaugg, Julian
Gartrell, Kyana
Alexandersen, Soren
Chamings, Anthony
Wang, Claire YT
Clark, Julia
Grimwood, Keith
Heney, Claire
Schlapbach, Luregn
Ware, Robert S
et al.
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
Size
File type(s)
Location
Abstract
BACKGROUND: A novel human parechovirus 3 Australian recombinant (HPeV3-AR) strain emerged in 2013 and coincided with biennial outbreaks of sepsis-like illnesses in infants. We evaluated the molecular evolution of the HPeV-AR strain and its association with severe HPeV infections. METHODS: HPeV3-positive samples collected from hospitalized infants aged 5-252 days in two Australian states (2013-2020) and from a community-based birth cohort (2010-2014) were sequenced. Coding regions were used to conduct phylogenetic and evolutionary analyses. A recombinant-specific PCR was designed and utilized to screen all clinical and community HPeV3-positive samples. RESULTS: Complete coding regions of 54 cases were obtained, which showed the HPeV3-AR strain progressively evolving, particularly in the 3' end of the non-structural genes. The HPeV3-AR strain was not detected in the community birth cohort until the initial outbreak in late 2013. High-throughput screening showed most (>75%) hospitalized HPeV3 cases involved the AR strain in the first three clinical outbreaks, with declining prevalence in the 2019-20 season. The AR strain was not statistically associated with increased clinical severity amongst hospitalised infants. DISCUSSION: The HPeV3-AR was the dominant strain during the study period. Increased hospital admissions may have been from a temporary fitness advantage and/or increased virulence.
Journal Title
The Journal of Infectious Diseases
Conference Title
Book Title
Edition
Volume
227
Issue
2
Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Item Access Status
Note
Access the data
Related item(s)
Subject
Infectious diseases
Biological sciences
Biomedical and clinical sciences
Health sciences
Science & Technology
Life Sciences & Biomedicine
Immunology
Microbiology
Persistent link to this record
Citation
Bialasiewicz, S; May, M; Tozer, S; Day, R; Bernard, A; Zaugg, J; Gartrell, K; Alexandersen, S; Chamings, A; Wang, CYT; Clark, J; Grimwood, K; Heney, C; Schlapbach, L; Ware, RS; et al., Novel Human Parechovirus 3 Diversity, Recombination, and Clinical Impact Across 7 Years: An Australian Story, The Journal of Infectious Diseases, 2022, 227 (2), pp. 278-287